Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

This study has been completed.
Information provided by (Responsible Party):
Dynavax Technologies Corporation Identifier:
First received: January 23, 2007
Last updated: August 23, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2008
  Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)